Table 2. Clinical outcomes for the 41 Haarlem3 MDR-TB outbreak patients that had received a 2-year second line anti-TB chemotherapy.
| All outcomes (n = 41) | Treatment success (n = 24) | Unsuccessful treatment outcomes (n = 17) | P value | |
|---|---|---|---|---|
| Age (mean) | 31.15 (12.764) | 31.17 (12.139) | 31.12 (13.982) | 0.991 |
| <30 | 25 (61.0%) | 14 (58.3%) | 11 (64.7%) | |
| 30–50 | 11 (26.8%) | 05 (20.8%) | 6 (35.3%) | 0.112 |
| >50 | 05 (12.2%) | 05 (20.8%) | 0 (0.0%) | |
| Male | 36 (87,8%) | 19 (79.2%) | 17 (100%) | 0.065 |
| Smoking history | 28 (68.3%) | 14 (58.3%) | 14 (82,4%) | 0.173 |
| Employed | 25 (61%) | 15 (62.5%) | 10 (58.8%) | 1.000 |
| Epidemiological link with MDR cases | 11 (26.8%) | 5 (20.8%) | 6 (35.3%) | 0.476 |
| Positive AFB smear prior to SLD* | 17 (41.5%) | 6 (25.0%) | 11 (64.7%) | 0.023 |
| Pre-SLD* Finding of CXR | ||||
| Cavitary lesions | 6 (14.6%) | 3 (12.5%) | 3 (17.6%) | 0.679 |
| Pleural effusion | 4 (9.8%) | 3 (12.5%) | 1 (5.9%) | 0.629 |
| Bilateral lesions | 16 (39.0%) | 8 (33.3%) | 8 (47.1%) | 0.518 |
| Unilateral | 15 (36.6%) | 10 (41.7%) | 5 (29.4%) | 0.679 |
| Comorbidities | ||||
| Diabetes | 4 (9.8%) | 2 (8.3%) | 2 (11.8%) | 1.000 |
| Respiratory diseases other than TB | 6 (14.6%) | 4 (16.7%) | 2 (11.8%) | 1.000 |
| Cancer | 5 (12.2%) | 2 (8.3%) | 3 (17.6%) | 0.633 |
| Others | 12 (29.3%) | 6 (25.0%) | 6 (35.3%) | 0.507 |
| Resistance to pyrazinamide | 29 (70.7%) | 15 (62.5%) | 14 (82.4%) | 0.296 |
| IS6110 RFLP profile | ||||
| 11-banded | 31 (75.6%) | 21 (87.5%) | 10 (58.8%) | 0.063 |
| 12-banded | 10 (24.4%) | 3 (12.5%) | 7 (41.2%) | |
| Previous or present incarceration | 12 (29.3%) | 6 (25.5%) | 6 (35.3%) | 0.507 |
| Prior DOTS treatment | 29 (70.7%) | 15 (62.5%) | 14 (82.4%) | 0.296 |
| Poor adherence to treatment | 22 (53.7%) | 8 (33.3%) | 14 (82.4%) | 0.004 |
*SLD: Second-line drugs.
Significant P values are shown in bold.